INTRODUCTION
Primary nonsenlinomatous testicular germ cell tumors (NSs) of adults are, in general, tumors with mixed histology. They can be composed of embryonal carcinoma (EC), yolk sac tumor (YS), choriocarcinoma (CH), immature teratoma (IT), and mature teratoma (MT) [1, 2] . A seminoma (SE) component may be present. Pure NSs, with one histological component, are rare [3] . At presentation, about 70 to 75% of patients with NSs have lymphatic and/or hematogenous metastases. However, NSs are highly curable solid tumors. The patients are treated by orchidectomy, in case of metastatic disease, followed by cisplatin-containing chemotherapy and additional surgical resection of residual mass [4] .
From metastases of primary NSs treated with chemotherapy, often residual mature teratoma (RMT) is left. RMT is composed of fully differentiated, mature somatic tissue. As is the case in primary tumors, untreated metastases of primary NSs rarely consist exclusively of mature somatic tissue; they usually retain the histology of the primary tumor [5] . Apparently, after chemotherapy there is a shift towards higher degrees of differentiation. This effect of chemotherapy might be due to the induction of differentiation of malignant cells to more differentiated cells, to selective destruction of cells other than MT cells, or to selection of cells with an inherent capacity of (therapyrelated) differentiation. The mechanisms are not mutually exclusive [6] .
Cytogenetic comparison of primary tumors and metastases may indicate chromosomal changes playing a role in tumor progression. Tumor progression is the result of clonal evolution of a tumor cell population, paralleled by karyotype evolution [7] .
We compared the cytogenetically abnormal karyotypes of a series of 70 NSs with those of 31 RMTs, in order to 0165-4608/97/$17.00 PII S0165-4608(96)00440-2 study chromosomal changes playing a role in tumor progression (e.g., metastasis) and/or the mechanism(s) involved in therapy-related differentiation. A distinction between both events cannot be made because, due to the application of standardized clinical protocols, we are not able to investigate the chromosomal pattern of untreated metastases of NSs.
MATERIALS AND METHODS
A cytogenetic comparison of 70 NSs with 31 RMTs was carried out. Culturing and harvesting of the tumors was performed using standard cytogenetic techniques [8, 9] . For each tumor, a modal composite karyotype description was made according to the ISCN 1995 [10] . However, all karyotype descriptions are based on the triploid level, since this makes over-and underrepresentation of specific chromosomes--an important feature of testicular germ cell tumors [9, 11] --better visible and comparable. Only NSs and RMTs with an abnormal karyotype are included in this study, because NSs and RMTs show a consistently high DNA index (DI) [12] [13] [14] [15] [16] .
For each tumor and chromosome, the average number of short and long arms was determined. Parts of chromosomal arms involved in structural abnormalities were reg-
Modal Case
Description of modal composite karyotype number 21 56-60,XXY,der(1)t(1;4)(p11;q11),-2,add(2)(p25),-4,-5,-6,-6,dup(7)(q11.2q21),+8,-9,-10, 59 -11,add (11) 57-62,XXY,add(1)(p13),add(2)(q11),-3,add(3)(q26),-4,add(5)(q35),add(7)(p22),der(7) 58 t(7;7;18)(Tqter-~7p22::7qll--Wq34::18q11-~18qter),+add(8)(p23),-9,-10,-13,add(14) (q32),-15,-18,-18,der (18) 56-62,XXY,+Y,add(1)(pll),add(2)(q13),-3,-4,-5,-6,add(6)(q16),+add(7)(q32),-9,der(9) 60 t(6;9)(q11;q21),der(10)t(9;10)(q21;q21)-11,+i (12)(p10) aCases I to 13 have been described previously (Castedo et el. [17] ) istered as whole arms if they represented 50% or more of the total arm length. The modal number of short and long arms divided by two revealed the average modal number of chromosomes. The average number of sex chromosomes for each tumor was multiplied by two to allow comparison with the autosomes [9, 11] .
Statistical analysis and comparison of the cytogenetic data of the NSs and RMTs was performed using the Mann- 
RESULTS

Karyotypes
The modal composite karyotypes and the modal chromosome numbers for the 31 chromosomally abnormal cases of RMTs are given in Table 1 . Cases 1 to 13 have been published [17] , as well as the 70 chromosomally abnormal NSs [9] . 
Statistical Analysis and Comparison of NSs and RMTs
The Mann-Whitney U test showed no significant difference between the modal total chromosome number in NSs (average, 65.0; standard deviation [SD], 13.5; n = 70) and RMTs (average, 60.5; SD, 6.5; n = 31) (p > 0.053). Figure 1 clearly shows that the average number of copies of the different chromosomes is highly similar in the series of NSs and RMTs (Spearman rank correlation: 0.918, p < 0.001). In RMTs and NSs, a similar pattern of overrepresentation (e.g., chromosomes 7, 8, 12, 21, and X) and underrepresentation (e.g., 11, 13, 18, and Y) is present. Additionally, Figure 2 shows this similar pattern of over-and underrepresentation of (parts of) chromosomes ( Fig. 2A has been published before [9] ). Chromosome arm 12p was clearly overrepresented, mainly due to i(12p), in NSs and RMTs. No significant difference in number of copies of the different chromosomes was observed when groups of NSs without a teratoma component (n = 12), NSs with a teratoma component (n = 58), and RMTs (n = 31) were compared (p > 0.05). Both the frequency of i(12p) (83% in NSs and 81% in the RMTs) as well as the average copy number of i(12p) (1.7; SD, 1.0 in the NSs and 1.5; SD, 0.9 in the RMTs) did not differ significantly between NSs and RMTs (p > 0.05). Figure 3 shows the number and location of breakpoints in each chromosome in the 70 NSs and 31 RMTs. The distribution of breakpoints in both groups does not differ significantly (p > 0.001). In both the NSs and RMTs, a L  L  I  L  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I   2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y   chromosome  number clustering of breakpoints was found in chromosome 1 and 12 (p ~ 0.001); for chromosome 12, mainly due to i(12p).
--
DISCUSSION
Cytogenetic comparison of primary tumors and metastases may indicate chromosomal changes playing a role in tumor progression. Tumor progression is the result of clonal evolution of a tumor cell population and is paralleled by karyotype evolution [7] . Due to clonal evolution and selection, malignant tumors are genetically heterogeneous and contain multiple subpopulations of cancer cells. Only certain subpopulations of tumor cells have the capacity to form metastatic lesions [18] . Due to the application of standardized clinical protocols, we are not able to investigate the chromosomal pattern of untreated metastases of NSs. It is only possible to study residual lesions following chemotherapy--often residual mature teratoma (RMT). These RMT lesions are composed of fully differentiated tissue [6] . This higher degree of differentiation after chemotherapy treatment might be due to direct induction of differentiation of malignant cells to fully differentiated cells, to selective destruction of cells other than MT cells, or to selection of cells with an inherent capacity of spontaneous differentiation or capacity of therapy-related differentiation [6, 17, [19] [20] [21] . A cytogenetic comparison between NSs and RMTs may shed light on the chromosomal changes playing a role in tumor progression and on the mechanism(s) of therapyrelated differentiation, although a distinction between these events cannot be made.
The present study, a cytogenetic comparison of a series of 70 NSs and 31 RMTs, revealed no significant chromosomal differences between the two groups. This may be explained in different ways.
First, by clonal dominance. This means that during progression a primary tumor gradually becomes overgrown by the progeny of a metastatic clone. This primary tumor consists almost exclusively of cells of this dominant metastatic clone and is biologically equivalent to the metastasis [22] . The cells of the primary tumor and the metastasis will show identical or very similar karyotypes. Under the influence of therapy, the metastatic cells differentiate irrespective of their highly abnormal karyotype.
Second, the observed chromosomal similarities between NSs and RMTs might be due to in vitro selection during culture. The histology of primary NSs in general is heterogeneous. RMT is most often found when the primary tumor contains MT [6] . It might be that this MT component populates the RMT and is selected in the culture of the primary NS.
Third, one would not expect to find chromosomal differences between primary NSs and RMTs, when metastasis is not caused or accompanied by visible chromosomal alterations and when RMTs are the result of therapyrelated induction of differentiation of cells, irrespective of their chromosomal pattern [17] . If RMTs are the result of selection or of differentiation of selected cells with an abnormal chromosomal pattern, but with a proper balanced chromosomal constitution allowing differentiation, one might only expect specific chromosomal differences between the primary NSs and RMTs [17] when different directions or degrees of differentiation are brought about by differences in chromosomal pattern. However, in an NS and a metastatic NS, respectively, we observed comparable karyotypes in the different pure histological components, which were karyotyped separately [23, 24] . Furthermore, in our series of NSs with pure histology [9] , although small, we have no indications that the different histological components have different specific chromosomal constitutions. These data suggest that, in NSs, differences in direction of differentiation are not accompanied by gross chromosomal changes. Therefore, when RMTs are the result of differentiation of selected cells, and when metastasizing and differentiation are not paralled by visible chromosomal alterations, one also may observe common karyotypes between the primary NSs and RMTs.
So, based on cytogenetics, both induction of differentiation or selection of cells with capacity to differentiate are possible mechanisms for the therapy-related differentiation of RMTs. In two different studies, Oosterhuis et al. [6, 12, 25] found their results being compatible with selection as the mechanism of therapy-related differentiation.
In a previous cytogenetic comparison of a series of 14 NSs and 13 RMTs, we observed some differences between NSs and RMTs (e.g., smaller over-and underrepresentation of specific chromosomes and less i(12p)-copies and breakpoints in RMTs than in NSs). These findings lead us to conclude that RMTs are the result of selection of clones with a less abnormal karyotype and possibly the right balance of genes allowing differentiation [17] . In our present, much larger series of NSs and RMTs, we found no evidence for the selection of clones with a less abnormal karyotype. However, selection of cells is still a possible mechanism.
Murty et al. [26] found that well-differentiated teratomas exhibited a significantly higher level of allelic loss compared to the less differentiated embryonal carcinomas. Their results led them to suggest that nonrandom loss or inactivation of certain genes may be associated with tumor development and that loss or inactivation of other genes may be associated with somatic differentiation. Cytogenetically, we did not find a significant difference in loss of specific chromosomal parts in RMTs compared to primary NSs with different histologies.
In conclusion, the two groups of primary NSs and RMTs showed comparable chromosomal patterns. We found no cytogenetic evidence for specific chromosomal alterations to be related to the progression of primary NSs to metastasis and/or therapy-related differentiation. Both induction of differentiation of (selected) cells or selection of cells with capacity to differentiate are possible mechanisms for the therapy-related differentiation of RMTs. Genetic changes not detectable at the chromosomal level or epigenetic factors may play a role in the tumor progression and/or in the therapy-related differentiation of these tumors. It might be that most chromosomal changes related with tumor progression in NSs take place very early during tumor development, probably when the non-inva- Over-and underrepresentation of (parts of) chromosomes in 70 NSs (A) [9] and 31 RMTs (B). The autosomes are calculated on the basis of a triploid DNA content (expected number is three), while the sex chromosomes are calculated on the basis of a diploid DNA content (expected number is one). The relative overrepresented regions are indicated per tumor on the right side of the chromosomes, while the underrepresented regions are indicated on the left side. The copy number of 12p, due to i(12p), is indicated inside a rectangle. sive precursor, carcinoma in situ, develops into invasive tumor.
